Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Files An 8-K Submission of Matters to a Vote of Security Holders
ITEM5.07. Submission of Matters to a Vote of Security Holders.
On June 8, 2017, the Company held its Annual Meetingat 11570 6th
Street, Rancho Cucamonga, California 91730. The stockholders of
the Company voted on the following items at the Annual Meeting:
|
1. |
To elect three Class I directors to serve until the 2020 |
|
2. |
To ratify the appointment of Ernst Young LLP as the |
The voting results for each of these proposals are detailed
below.
1. Election of Directors
|
Nominee |
For |
Against |
Abstained |
Broker Non-votes |
|
Jason B. Shandell |
26,699,542 |
5,035,303 |
5,161 |
8,686,975 |
|
Richard Koo |
26,932,937 |
4,801,898 |
5,171 |
8,686,975 |
|
Floyd F. Petersen |
27,377,909 |
4,356,886 |
5,211 |
8,686,975 |
Each director nominee was duly elected to serve until the 2020
annual meeting of stockholders and until his or her successor is
duly elected and qualified.
2. Ratification of Appointment of Independent Registered Public
Accounting Firm
|
For |
Against |
Abstained |
Broker Non-votes |
|
40,380,827 |
14,393 |
31,761 |
N/A |
The stockholders ratified the appointment of Ernst Young LLP as
the Companys independent registered public accounting firm for
the fiscal year ending December 31, 2017.
About Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.
